Table 1 Characteristics of the PCSK9iG subjects according to their initial glucose metabolism status
From: Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
Total n = 218 | Normoglycaemia n = 91 | Pre-DM n = 77 | DM n = 50 | p | |
|---|---|---|---|---|---|
Age (years) | 62 (54–69) | 59 (51–67) | 62 (54–69) | 66 (58–72) | 0.001 |
Sex (male, %) | 53.2 | 58.2 | 45.5 | 56 | 0.230 |
Baseline BMI (kg/m2) | 29 ± 4.6 | 27.7 ± 4.5 | 29.8 ± 4.8 | 30.4 ± 3.9 | 0.001 |
Final BMI (kg/m2) | 29 ± 4.7 | 27.8 ± 4.7 | 29.7 ± 4.8 | 30.1 ± 4.3 | 0.004 |
CVD (%) | 53.2 | 45.1 | 48.1 | 76 | 0.001 |
FH (%) | 70.6 | 69.2 | 76.6 | 64 | 0.289 |
Ezetimibe (%) | 62.8 | 56 | 68.8 | 66 | 0.202 |
Statins (%) | 73.4 | 70.3 | 77.9 | 72 | 0.523 |
PCSK9i starting dose (%) | 0.005 | ||||
Al 75 mg Al 150 mg E 140 mg | 37.6 31.2 31.2 | 34.1 23.1 42.9 | 40.3 31.2 28.6 | 40 46 14 | |
Lp(a) (mg/dL) | 40.6 (11.2–98.8) | 57.4 (10.6-100.6) | 23 (9.2–84) | 48 (14–108) | 0.509 |
LDL-C (mg/dL) | 158.1 (130.8-191.1) | 157 (129–190) | 173.3 (141.9-202.6) | 153.1 (127.5-172.2) | 0.009 |
Fasting glucose (mg/dL) | 100 (91–114) | 91 (86-95.5) | 107 (100–112) | 130 (114–160) | < 0.001 |
A1c (%) N = 151 | 5.9 (5.6–6.4) | 5.5 (5.3–5.6) | 5.8 (5.6–6.1) | 6.7 (6.4–7.8) | < 0.001 |